Maxim Group analyst Anthony Vendetti maintained a Buy rating on Viveve Medical Inc (NASDAQ: VIVE) today and set a price target of $9. The company’s shares opened today at $3.10.
Vendetti commented:
“We believe VIVE has completed enrollment of the first 25 patients in its VIVEVE II study. The company expects to submit the 30-day safety data to the FDA by the end of June 2018. Market open, VIVE announced it reached a settlement of its patent infringement lawsuit against ThermiGen, LLC (Thermi), under which VIVE will receive both a monetary payment and royalties from Thermi.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 11.1% and a 58.8% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Restoration Robotics Inc, Xtant Medical Holdings, and Milestone Scientific.
Viveve Medical Inc has an analyst consensus of Strong Buy, with a price target consensus of $7.
See today’s analyst top recommended stocks >>
Based on Viveve Medical Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $12.67 million. In comparison, last year the company had a GAAP net loss of $6.7 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viveve Medical, Inc. engages in the provision of health products. Its activities include development and distribution of women’s health solutions. Its products include non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The company was founded on March 3, 1987 and is headquartered Sunnyvale, CA.
